Financials data is unavailable for this security.
View more
Year on year GemPharmatech Co Ltd had net income fall -3.48% from 164.64m to 158.91m despite a 20.45% increase in revenues from 516.55m to 622.19m. An increase in the cost of goods sold as a percentage of sales from 29.08% to 32.60% was a component in the falling net income despite rising revenues.
| Gross margin | 65.18% |
|---|---|
| Net profit margin | 23.65% |
| Operating margin | 23.91% |
| Return on assets | 6.29% |
|---|---|
| Return on equity | 7.59% |
| Return on investment | 7.30% |
More ▼
Cash flow in CNYView more
In 2023, GemPharmatech Co Ltd increased its cash reserves by 32.83%, or 138.40m. The company earned 116.57m from its operations for a Cash Flow Margin of 18.74%. In addition the company generated 39.29m cash from financing while 18.61m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.17 |
|---|---|
| Tangible book value per share | 5.04 |
More ▼
Balance sheet in CNYView more
| Current ratio | 4.09 |
|---|---|
| Quick ratio | 3.96 |
| Total debt/total equity | 0.074 |
|---|---|
| Total debt/total capital | 0.0689 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 290.24% while earnings per share excluding extraordinary items fell by -3.48%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend.
| Div yield(5 year avg) | 0.19% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 49.22% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -0.5822 |
More ▼
